2-氯-N-(3-(三氟甲基)苯基)烟酰胺 | 53062-99-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-N-(3-(三氟甲基)苯基)烟酰胺
• 英文名称: 2-Chloronicotinic acid 3-trifluoromethylanilide
• 英文别名: (2-chloro-(3-pyridyl))-N-(3-trifluoromethyl-phenyl)-carboxamide；2-chloro-N-(3-(trifluoromethyl)phenyl)nicotinamide；2-chloro-N-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide
• CAS: 53062-99-0
• 化学式: C₁₃H₈ClF₃N₂O
• mdl: MFCD00731881
• 分子量: 300.668
• InChiKey: HEAVOBMAHAYADT-UHFFFAOYSA-N

物化性质

• 熔点：
  118-119 °C
• 沸点：
  312.1±42.0 °C(Predicted)
• 密度：
  1.452±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-甲氨基吡啶 、 2-氯-N-(3-(三氟甲基)苯基)烟酰胺 在 氩 、 碳酸氢钠 、 乙酸乙酯 、 Sodium sulfate-III 、 crude product 、 silica gel 、 Isopropyl alcohol isopropyl ether 作用下， 以 乙酸乙酯 为溶剂， 反应 16.0h， 以to give the title compound as a colourless crystalline solid, m.p. 152-153° C.的产率得到N-[3-trifluoromethyl-phenyl]{2-[(4-pyridylmethyl)-amino](3-pyridyl)}-carboxamide
  参考文献：
  名称：

  2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors

  摘要：

  本发明涉及使用式I的2-氨基烟酰胺衍生物，其中n为1至6（含1和6）；W为O或S；R1和R3分别独立表示氢、低级烷基或低级酰基；R2表示环烷基、芳基或含有一个或多个环氮原子和0、1或2个异原子（选自氧和硫）的单环或双环杂芳基，上述基团均未取代或单取代或多取代；R和R′分别独立表示氢或低级烷基；X表示芳基或含有一个或多个环氮原子和0、1或2个异原子（选自氧和硫）的单环或双环杂芳基，上述基团均未取代或单取代或多取代；或者其N-氧化物、可能的互变异构体或其药学上可接受的盐，单独或与一种或多种其他药物活性化合物联合使用，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制有反应的疾病的药物组合物；以及式I的新2-氨基烟酰胺衍生物及其制备方法。

  公开号：

  US06624174B2
• 作为产物：
  描述：

  2-氯烟酰氯 、 间氨基三氟甲苯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 2-氯-N-(3-(三氟甲基)苯基)烟酰胺
  参考文献：
  名称：

  Substituted alkylamine derivatives and methods of use

  摘要：

  选定的胺对预防治疗疾病有效，如血管生成介导的疾病。本发明包括新的化合物、类似物、前药和药用可接受的盐，药物组合物和预防治疗疾病和其他疾病或状况的方法，包括癌症等。本发明还涉及制造这类化合物的过程以及在此类过程中有用的中间体。

  公开号：

  US20030225106A1

文献信息

• 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20030032656A1

  公开（公告）日：2003-02-13

  The invention relates to the use of 2-amino-nicotinamide derivatives of formula (I) wherein n is from 1 up to and including 6; W is O or S; R 1 and R 3 represent independently of each other hydrogen, lower alkyl or lower acyl; R 2 represents a cycloalkyl group, an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; R and R′ are independently of each other hydrogen or lower alkyl; X represents an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; or a N-oxide, a possible tautomer thereof or a pharmaceutically acceptale salt of such a compound, alone or in combination with one or more other pharmaceutically active compounds for the preparation of a pharmaceutical composition for use for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity; and to new 2-amino-nicotinamide derivatives of formula (I) and processes for the preparation thereof. 1

  本发明涉及使用公式（I）中的2-氨基烟酰胺衍生物，其中n为1至6，包括1和6；W为O或S；R1和R3分别表示氢、低烷基或低酰基；R2表示环烷基、芳基或含有一个或多个环氮原子和0、1或2个异原子的单环或双环杂芳基，这些基团在每种情况下都未取代或单取代或多取代；R和R'独立地表示氢或低烷基；X表示芳基或含有一个或多个环氮原子和0、1或2个异原子的单环或双环杂芳基，这些基团在每种情况下都未取代或单取代或多取代；或其N-氧化物、可能的互变异构体或其药学上可接受的盐，单独或与一个或多个其他药物活性化合物结合，用于制备用于治疗对抗VEGF受体酪氨酸激酶活性的抑制有反应的疾病的制剂；以及公式（I）的新型2-氨基烟酰胺衍生物及其制备方法。
• [EN] 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS<br/>[FR] DERIVES DE 2-AMINO-NICOTINAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE TYROSINE KINASE DU RECEPTEUR VEGF
  申请人：NOVARTIS AG

  公开号：WO2001055114A1

  公开（公告）日：2001-08-02

  The invention relates to the use of 2-amino-nicotinamide derivatives of formula (I) wherein n is from 1 up to and including 6; W is O or S; R1 and R3 represent independently of each other hydrogen, lower alkyl or lower acyl; R2 represents a cycloalkyl group, an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; R and R' are independently of each other hydrogen or lower alkyl; X represents an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; or a N-oxide, a possible tautomer thereof or a pharmaceutically acceptale salt of such a compound, alone or in combination with one or more other pharmaceutically active compounds for the preparation of a pharmaceutical composition for use for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity; and to new 2-amino-nicotinamide derivatives of formula (I) and processes for the preparation thereof.

  本发明涉及使用式(I)的2-氨基烟酰胺衍生物，其中n为1至6，包括1和6；W为O或S；R1和R3各自独立地表示氢、低级烷基或低级酰基；R2表示环烷基、芳基或含有一个或多个环氮原子和0、1或2个异原子的单环或双环杂芳基，所述异原子独立地选自氧和硫的群，每种基团都未取代或单取代或多取代；R和R'各自独立地表示氢或低级烷基；X表示芳基或含有一个或多个环氮原子和0、1或2个异原子的单环或双环杂芳基，所述异原子独立地选自氧和硫的群，每种基团都未取代或单取代或多取代；或其N-氧化物，其可能的互变异构体或其药学上可接受的盐，单独或与一种或多种其他药物活性化合物结合，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制有反应的疾病的药物组合物；以及式(I)的新2-氨基烟酰胺衍生物及其制备方法。
• Substituted amine derivatives and methods of use
  申请人：——

  公开号：US20030195230A1

  公开（公告）日：2003-10-16

  Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择性胺类化合物对于预防和治疗由血管生成介导的疾病等疾病是有效的。该发明包括新的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗涉及癌症等疾病和其他疾患或病况的方法。该发明还涉及制备这种化合物的过程，以及在这些过程中有用的中间体。
• 2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors
  申请人：Novartis AG

  公开号：US06624174B2

  公开（公告）日：2003-09-23

  The invention relates to the use of 2 amino-nicotinamide derivatives of formula I wherein n is from 1 up to and including 6; W is O or S; R1 and R3 represent independently of each other hydrogen, lower alkyl or lower acyl; R2 represents a cycloalkyl group, an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; R and R′ are independently of each other hydrogen or lower alkyl; X represents an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted; or a N-oxide, a possible tautomer thereof or a pharmaceutically acceptable salt of such a compound, alone or in combination with one or more other pharmaceutically active compounds for the preparation of a pharmaceutical composition for use for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity; and to new 2-amino-nicotinamide derivatives of formula I and processes for the preparation thereof.

  本发明涉及使用式I的2-氨基烟酰胺衍生物，其中n为1至6（含1和6）；W为O或S；R1和R3分别独立表示氢、低级烷基或低级酰基；R2表示环烷基、芳基或含有一个或多个环氮原子和0、1或2个异原子（选自氧和硫）的单环或双环杂芳基，上述基团均未取代或单取代或多取代；R和R′分别独立表示氢或低级烷基；X表示芳基或含有一个或多个环氮原子和0、1或2个异原子（选自氧和硫）的单环或双环杂芳基，上述基团均未取代或单取代或多取代；或者其N-氧化物、可能的互变异构体或其药学上可接受的盐，单独或与一种或多种其他药物活性化合物联合使用，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制有反应的疾病的药物组合物；以及式I的新2-氨基烟酰胺衍生物及其制备方法。
• Substituted pyridinecarboxamides for the treatment of cancer
  申请人：Amgen Inc.

  公开号：US08058445B2

  公开（公告）日：2011-11-15

  Selected pyridine carboxamide compounds of Formula XI are effective for treatment of diseases and other maladies or conditions involving, cancer and the like.

  Formula XI中选择的吡啶羧酰胺化合物对治疗涉及癌症等疾病和其他病症或情况有效。